Food and Drug Administration--Press Releases

• FDA and industry reach agreement in principle on medical device user fees
  
• FDA approves Gleevec for expanded use in patients with rare gastrointestinal cancer
  
• FDA approves Kalydeco to treat rare form of cystic fibrosis
  
• FDA takes action against New York cheese manufacturer
  
• FDA approves new treatment for most common type of skin cancer
  
• FDA approves Inlyta to treat patients with a type of advanced kidney cancer
  
• Department of Justice files Consent Decree of Permanent injunction against Ranbaxy
  
• Maine company holds cold smoked salmon product after FDA order
  
• FDA permits marketing of first test for risk of rare brain infection in some people treated with Tysabri
  
• FDA approves Voraxaze to treat patients with toxic methotrexate levels
  
• FDA completes work on three drug user fee programs
  
• FDA expands use of endovascular graft to treat aortic tears
  
• FDA to protect important class of antimicrobial drugs for treating human illness
  
• FDA expands use of Prevnar 13 vaccine for people ages 50 and older
  
• FDA to approve shared system REMS for TIRF products
  
• FDA: Chicago-area sandwich manufacturer agrees to stop production
  
• FDA expands use of HIV drug Isentress to children and adolescents
  
• FDA: Do not use ShoulderFlex Massager
  
• FDA collaboration to monitor rare eye condition associated with cataract surgery
  
• FDA approves mechanical cardiac assist device for children with heart failure